Behavioral Intervention
Resistance Training for Chronic Kidney Disease
This trial aims to test whether a 12-week high-velocity resistance training program is safe and practical for older adults with advanced chronic kidney disease. The study will compare this program to a control group attending
Vitamin D Analog
Calcitriol vs Vitamin D for Kidney Failure
"This trial compares the effects of two different treatments on patients with kidney failure and high levels of parathyroid hormone. One group will receive a fixed dose of oral calcitriol, while the other
Behavioural Intervention
Patient-centered Care for Acute Kidney Injury
This trial will compare a new intervention to usual care to see if it helps people avoid hospital visits for up to 90 days. It will test how it affects kidney health and patient reported outcomes. 2145 people will be randomly assigned to the study.
NAD+ precursor
NAD Augmentation for Diabetic Kidney Disease
This trial is testing whether NMN, a compound that may improve cell function, can help older adults with type 2 diabetes and high urine protein levels. The goal is to see if NMN can reduce kidney damage by improving cell energy production. Participants will receive NMN to compare the effects.
Popular Filters
Trials for CKD Patients
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Empagliflozin for Kidney Failure
This trial will test the safety of empagliflozin in dialysis patients; results may lead to a larger clinical trial to explore the potential heart benefits of empagliflozin.
Immunosuppressant
Fingolimod for Kidney Transplant Rejection
This trial tests if fingolimod can help new kidney transplant patients by preventing kidney damage and improving transplant success. Fingolimod works by blocking harmful pathways in the body. The study aims to see if this treatment is safe and effective over time. Fingolimod has been used in multiple sclerosis treatment and is known for its immunomodulating effects, but it has significant potential side effects.
Monoclonal Antibody
Anti-Factor XI Monoclonal Antibody for Kidney Failure
This trial is testing MK-2060, a medicine that blocks a blood protein, on patients with severe kidney disease. The goal is to see if it can prevent clots and keep the treatment method effective for a longer period.
Behavioural Intervention
Communication Tool Training for Kidney Failure
This trial will test whether the "Best Case/Worse Case" communication tool can help patients with end-stage renal disease receive appropriate palliative care and improve communication between patients and their caregivers.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Trials for Chronic Kidney Failure Patients
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Empagliflozin for Kidney Failure
This trial will test the safety of empagliflozin in dialysis patients; results may lead to a larger clinical trial to explore the potential heart benefits of empagliflozin.
Immunosuppressant
Fingolimod for Kidney Transplant Rejection
This trial tests if fingolimod can help new kidney transplant patients by preventing kidney damage and improving transplant success. Fingolimod works by blocking harmful pathways in the body. The study aims to see if this treatment is safe and effective over time. Fingolimod has been used in multiple sclerosis treatment and is known for its immunomodulating effects, but it has significant potential side effects.
Monoclonal Antibody
Anti-Factor XI Monoclonal Antibody for Kidney Failure
This trial is testing MK-2060, a medicine that blocks a blood protein, on patients with severe kidney disease. The goal is to see if it can prevent clots and keep the treatment method effective for a longer period.
Behavioural Intervention
Communication Tool Training for Kidney Failure
This trial will test whether the "Best Case/Worse Case" communication tool can help patients with end-stage renal disease receive appropriate palliative care and improve communication between patients and their caregivers.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Phase 3 Trials
SGLT2 Inhibitor
Sotagliflozin for Diabetic Kidney Disease
This trial aims to test the effects of a new drug called SOTA on kidney function in people with type 1 diabetes and moderate to advanced kidney disease. Previous studies have shown that SOTA can increase
Behavioral Intervention
Self-Managed Blood Pressure Control for Chronic Kidney Disease
This trial will test if patients can better manage their blood pressure with the help of a clinical pharmacist and if this lowers their blood pressure more than the standard care.
Calcium and Magnesium Supplement
Effervescent Calcium-Magnesium Citrate for End-Stage Renal Disease
This trial will explore whether effervescent calcium magnesium citrate (EffCaMgCit) can help people with end stage renal disease on hemodialysis by reducing the formation of calciprotein particles (CPP), which can cause heart and artery problems.
Trials With No Placebo
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Empagliflozin for Kidney Failure
This trial will test the safety of empagliflozin in dialysis patients; results may lead to a larger clinical trial to explore the potential heart benefits of empagliflozin.
Behavioural Intervention
Communication Tool Training for Kidney Failure
This trial will test whether the "Best Case/Worse Case" communication tool can help patients with end-stage renal disease receive appropriate palliative care and improve communication between patients and their caregivers.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Arteriovenous Graft
InnAVasc Graft for Kidney Failure
This trial will study if a new kind of dialysis access graft is safe and effective. The new graft has been designed to allow for immediate needle access, reduce excessive bleeding, and provide protection from improper needle cannulation attempts.
View More Related Trials
Frequently Asked Questions
Introduction to kidney failure
What are the top hospitals conducting kidney failure research?
When it comes to the battle against kidney failure, top hospitals across the United States are leading the charge in clinical trials and innovative research. In Cleveland, Ohio, the renowned Cleveland Clinic is currently conducting six active trials focused on kidney failure. While their history of kidney failure studies may be more recent with only two recorded trials thus far, they have wasted no time in making strides since their first trial in 2019. Vanderbilt University Medical Center in Nashville has also emerged as a key player in this field. With four ongoing clinical trials and an impressive total of 27 completed studies dating back to their inaugural trial in 1998, they have long been committed to advancing knowledge and treatment options for patients suffering from kidney failure.
Notably contributing to this cause is Clinical Advancement Center (CAC), PLLC located in San Antonio. This emerging center boasts four active clinical trials dedicated to finding breakthroughs for kidney failure patients while having conducted just two previous investigations since recording its first trial in 2014. The University of Florida's medical campus based in Gainesville similarly highlights its dedication through three ongoing clinical tests aimed at addressing kidney failure cases while adding up three different studies performed throughout these years from starting it's pioneering investigation on such conditions way back until2006.
Meanwhile, Emory University Hospital situated amidst Atlanta’s bustling medical scene joins the ranks with its own trio of active renal failure trials alongside three previously held studies that began shaping pathways towards progress from as early as2003.These top hospitals collectively demonstrate that significant efforts are being made nationwide not only to understand but also combat this challenging condition.
With each new study undertaken and every milestone achieved by these institutions comes renewed hope for individuals grappling with or at risk of developing kidney failure. Through tireless research and unwavering commitment, these hospitals continually strive toward improving treatments and quality of life for patients everywhere who are affected by this debilitating condition
Which are the best cities for kidney failure clinical trials?
In the realm of kidney failure clinical trials, several cities emerge as leading hubs for research and innovation. Houston, Texas takes the lead with 27 active trials, investigating promising treatments like MK-2060, Cohort 2, and Avelumab (MSB0010718C). Following closely behind is Los Angeles, California with 21 ongoing studies focusing on interventions such as Avelumab (MSB0010718C), MK-2060, and CIN-107. Chicago also makes its mark in this field with 19 active trials exploring options like Cohort 2 and Finerenone (BAY94-8862). These cities offer a wealth of opportunities for individuals battling kidney failure to participate in cutting-edge clinical trials that pave the way for improved care and potential breakthroughs.
Which are the top treatments for kidney failure being explored in clinical trials?
Kidney failure research is paving the way for potential breakthroughs, with several promising treatments currently being explored in clinical trials. MK-2060 has taken center stage, with two active trials and a total of five kidney failure trials since its introduction in 2019. Another contender making waves is semaglutide, showing promise with two ongoing trials and one all-time trial dedicated to kidney failure since its listing in 2023. Finally, empagliflozin enters the fray with two active trials and a modest but growing history of two kidney failure studies since it was first listed in 2018. These exciting developments bring hope to patients as researchers strive to find innovative solutions for managing and treating kidney failure globally.
What are the most recent clinical trials for kidney failure?
Recent clinical trials offer promising prospects for individuals with kidney failure. One notable trial focuses on an intervention group aiming to address the underlying causes and improve treatment outcomes. Another study examines the efficacy of a specific regimen tailored for patients with chronic kidney disease, offering potential advancements in managing this condition. Additionally, research explores the benefits of incorporating alkalizing fruit and vegetables into dietary plans as a complementary approach to support renal function. Furthermore, LY3437943 shows promise as a therapeutic option through its inclusion in phase 2 clinical trials. Lastly, Renal Autologous Cell Therapy (REACT) is being investigated in phase 1 trials for its potential to revolutionize treatment options by utilizing autologous cells derived from the patient's own body. With these innovative studies underway, there is renewed hope for improved interventions against kidney failure.
What kidney failure clinical trials were recently completed?
Several recent clinical trials have brought us closer to advancements in the treatment of kidney failure. Merck Sharp & Dohme LLC completed a trial for MK-2060 in May 2022, showcasing potential therapeutic options. Duke University's trial on Patiromer Oral Powder Product concluded successfully in June 2019, while Wake Forest University Health Sciences' study on Hemodialysis also reached completion during that same month. Notably, Merck Sharp & Dohme Corp.'s trial for MK-2060 wrapped up in April 2019 alongside Raymond Chung's glecaprevir/pibrentasvir treatment investigation. These significant findings pave the way for improved management strategies and renewed hope for individuals grappling with kidney failure.